


# Cardiovascular risk assessment in patients with type 2 diabetes

Cardiovascular risk assessment in patients with type 2 diabetes  
Individuals with T2DM are at a two- to four-fold higher risk of developing CVD during their lifetime alongside its manifestations CAD, stroke, HF, and AF, as well as peripheral artery diseases (PAD)

<b>Very high CV risk</b>	<p>Patients with T2DM with:</p> <ul style="list-style-type: none"> <li>• Clinically established ASCVD or</li> <li>• Severe TOD or</li> <li>• 10-year CVD risk <math>\geq 20\%</math> using SCORE2-Diabetes</li> </ul>
<b>High CV risk</b>	<p>Patients with T2DM not fulfilling the very high-risk criteria and a:</p> <ul style="list-style-type: none"> <li>• 10-year CVD risk 10 to <math>&lt;20\%</math> using SCORE2-Diabetes</li> </ul>
<b>Moderate CV risk</b>	<p>Patients with T2DM not fulfilling the very high-risk criteria and a:</p> <ul style="list-style-type: none"> <li>• 10-year CVD risk 5 to <math>&lt;10\%</math> using SCORE2-Diabetes</li> </ul>
<b>Low CV risk</b>	<p>Patients with T2DM not fulfilling the very high-risk criteria and a:</p> <ul style="list-style-type: none"> <li>• 10-year CVD risk <math>&lt;5\%</math> using SCORE2-Diabetes</li> </ul>

In patients aged  $\geq 40$  years with T2DM without ASCVD or severe TOD, it is recommended to estimate 10-year CVD risk using the SCORE2-Diabetes algorithm

SCORE2-Diabetes integrates information on conventional CVD risk factors (i.e. age, smoking status, systolic blood pressure [SBP], and total and high-density lipoprotein [HDL]-cholesterol) with diabetes-specific information (e.g. age at diabetes diagnosis, HbA1c, and eGFR)



**Recommendation Table 2 — Recommendations for assessing cardiovascular risk in patients with type 2 diabetes**

Recommendations to assess cardiovascular risk in patients with diabetes	Class <sup>a</sup>	Level <sup>b</sup>
It is recommended to screen patients with diabetes for the presence of severe TOD. <sup>c,43,44</sup>	I	A
It is recommended to assess medical history and the presence of symptoms suggestive of ASCVD in patients with diabetes. <sup>53–55</sup>	I	B

*Continued*

In patients with T2DM without symptomatic ASCVD or severe TOD, <sup>c</sup> it is recommended to estimate 10-year CVD risk via SCORE2-Diabetes. <sup>4,50</sup>	I	B
---	---	---

© ESC 2023

# example

- Patient is a 52-year old African American woman with a past medical history of hypertension and rheumatoid arthritis.
- She is a past smoker, quit 10 years ago.
- Her mother had a stroke at age 62 years.
- Meds: hydrochlorothiazide 25 mg daily, methotrexate 7.5 mg weekly, folic acid 1 mg daily
- BP: 138/85 mmHg, BMI 30.2 kg/m<sup>2</sup> Lipids: total chol 236 mg/dL, HDL-C 44 mg/dL, LDL-C 142 mg/dL, TG 250 mg/dL Glucose: 110 mg/dL
- WNL Lifestyle: Diet is high in carbohydrates and saturated fats; no regular exercise; however, she states she walks her dog once a day for 3-4 blocks


**10-year ASCVD risk: 8.0% (intermediate risk)**

## Key challenges


- Although the patient is at the low end of intermediate risk, she has both elevation in LDL-C and triglycerides (mixed dyslipidemia) and risk enhancing factors: premature family history of stroke, rheumatoid arthritis, and metabolic syndrome.
- Need to convey that she falls within the risk range for starting statin therapy and the presence of risk enhancing factors further increases her risk.
- BP is not optimally controlled, and if she is adherent to current medication, we should discuss adding another medication.
- Lifestyle strategies can also improve risk reduction
- Patient conveys that she prefers not to take cholesterol medication; others have told her about muscle pain with statins.



## VISUAL REPRESENTATION OF ASCVD RISK SCORE



 8 out of 100 people like you will have a heart attack or stroke in the next 10 years

 92 out of 100 people like you will not have a heart attack or stroke in the next 10 years

## RISK REDUCTION BY THERAPY

